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Abstract
Background: Mutations in the p53 oncosuppressor gene are highly frequent in human cancers. These alterations
are mainly point mutations in the DNA binding domain of p53 and disable p53 from transactivating target genes
devoted to anticancer activity. Mutant p53 proteins are usually more stable than wild-type p53 and may not only
impair wild-type p53 activity but also acquire pro-oncogenic functions. Therefore, targeting mutant p53 to clear the
hyperstable proteins or change p53 conformation to reactivate wild-type p53 protein functions is a powerful anticancer
strategy. Several small molecules have been tested for p53 reactivation in mutant p53-carrying cells while studies
exploiting the effect of natural compounds are limited. Capsaicin (CPS) is the major constituent of peppers and
show antitumor activity by targeting several molecular pathway, however, its effect on mutant p53 reactivation
has not been assessed yet. In this study we aimed at investigating whether mutant p53 could be a new target of
capsaicin-induced cell death and the underlying mechanisms.
Methods: p53 levels were analysed by western blot upon capsaicin treatment in the presence of the autophagy
inhibitor chloroquine. The mutant p53 reactivation was evaluated by chromatin-immunoprecipitation (ChIP) assay
and semi-quantitative RT-PCR analyses of wild-type p53 target genes. The specific wild-type p53 activation was
determined by using the inhibitor of p53 transactivation function, pifithrin-α and siRNA for p53.
Results: Here, we show that capsaicin induced autophagy that was, at least in part, responsible of mutant p53
protein degradation. Abrogation of mutant p53 by capsaicin restored wild-type p53 activities over mutant p53
functions, contributing to cancer cell death. Similar effects were confirmed in cancer cells bearing tumor-associated
p53 mutations and in H1299 (p53 null) with overexpressed p53R175H and p53R273H mutant proteins.
Conclusion: These findings demonstrate for the first time that capsaicin may reduce mutant p53 levels and reactivate
wild-type p53 protein in mutant p53-carrying cells and the p53 reactivation contributes to capsaicin-induced cell death.
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Background
TP53 is the major tumor-suppressor gene that encodes
for a DNA-binding transcription factor that, upon activa-
tion, regulates sequence-specific target genes involved in
cell growth inhibition, senescence and apoptosis, providing
powerful intrinsic defence against cancer [1]. Thus, an in-
tact p53 pathway protects cells from tumorigenesis, reduces
tumor progression, and activates tumor cell response to an-
ticancer drugs [2]. Approximately 55 % of human tumors
have loss of wild-type (wt) p53 function mainly due to point
mutations in the DNA-binding domain (DBD) ([3, 4],
http://p53.iarc.fr), which partially or completely distort p53
protein conformation [5]. These findings indicate that the
presence of a functional wtp53 is incompatible with
neoplastic cell growth [6]. The major consequence of
mutations in the DBD is loss of p53 binding to the
canonical sequence-specific target genes with impairment
of wtp53 oncosuppressor functions. Mutant p53 (mutp53)
often accumulates to high levels in tumors [7] and such
hyperstable mutp53 proteins may acquire pro-oncogenic
functions contributing to tumor progression and resistance
to therapies [8, 9]. Thus targeting mutp53 is a promising
strategy for anticancer treatments. Some molecules have
been so far shown to target mutp53 for protein degradation
or conformation change, providing new insight on mutp53
reactivation [10, 11]. Therefore, the search of novel
mutp53-targeting molecules is an emergent field of re-
search due to the important implications in cancer therapy.
Numerous phytochemicals from nature have been in-
vestigated for their anticancer activities. Such natural
compounds may target multiple signaling pathways and
cancer-associated genes; for that reason, several preclin-
ical studies have suggested that natural compounds can
also increase the sensitivity of chemoresistant cancers to
chemotherapies [12]. In addition, natural compounds are
generally less toxic than synthetic drugs. Therefore, a better
understanding of their activities and molecular targets is
crucial to translate the use of natural compounds in clinic.
Capsaicin (8-methyl-N-vanillyl-6-noneamide) (CPS) is the
major constituent of peppers belonging to the genus
Capsicum and responsible for their spicy flavor and burn-
ing sensation, also known as pungency [13]. Capsaicin has
been shown to have antitumor activity in vitro and in vivo;
it is able to induce apoptosis through intracellular calcium
increase, reactive oxygen species generation, and disrup-
tion of mitochondrial membrane transition potential [14].
Moreover, a role of autophagy in capsaicin-triggered cell
death has been proposed [15]. Autophagy is a proteolytic
process that is activated during various conditions of cellu-
lar stress, including nutrient deprivation or DNA damage
to eliminate unfolded proteins or damaged organelles to
survive bioenergetic stress and/or induce cell death [16].
We have previously shown that autophagy is involved in
mutp53 degradation, with the consequence of changing
the balance between folded–misfolded p53 proteins and
therefore restore wild-type over mutant p53 functions
[17, 18]. In this study we aimed at investigating whether
mutp53 could be a new target of capsaicin-induced cell
death and the underlying mechanisms. We found that
CPS-induced cell death in mutant p53-carrying cells
was, at least in part, dependent on p53 reactivation, as
evidenced by experiments using siRNA interference for
p53. Mechanistically, we found that CPS triggered mutp53
degradation likely through autophagy. Moreover, CPS
restored wtp53 functions such as DNA binding and trans-
activation of target genes, that were inhibited by blocking
autophagy with chloroquine (CHQ). Inhibiting p53 trans-
activation with PFT-α impaired CPS-induced wtp53 acti-
vation. Finally, CPS improved the cancer cell response to
chemotherapeutic drug. These findings demonstrate that
mutp53 is a new target of capsaicin-induced cell death.
Methods
Cell culture and treatments
In this study human lung cancer cell line H1299 (p53
null) and the glioblastoma cell line U373 (expressing
p53 mutation R273H) were maintained in RPMI-1640
(Life Technology-Invitrogen, Carlsbad, CA, USA),
while human breast cancer cell line SKBR3 (expressing
p53 mutation R175H) was maintained in DMEM (Life
Technology-Invitrogen); all cell lines were supplemented
with 10 % heat-inactivated fetal bovine serum (FBS),
100 units/mL penicillin, 100 μg/mL streptomycin (Life
Technology-Invitrogen), and 2 mmol/LL-glutamine (Life
Technology-Invitrogen) in a humidified atmosphere with
5 % CO2 and 95 % air at 37 °C.
Unless otherwise indicated, chemicals were from Sigma-
Aldrich (St. Louis, MO, USA). Capsaicin (CPS) was dis-
solved in DMSO and used at 100 and 200 μM; the
inhibitor of autophagic protein degradation chloroquine
(CHQ) was dissolved in dH2O and used at 25 μM; the
p53 inhibitor pifithrin-α (PFT) [19] (ENZO Life Sciences,
Lausen, Switzerland) was dissolved in DMSO and used at
30 μM; the chemotherapeutic drugs adryamycin (ADR) and
cisplatin (CDDP) (Teva, Pharma Italia, Italy) were added to
the culture media, respectively, at 1.5 μg/ml and 2.5 μg/ml
for the indicated times, as previously reported [20].
Transfection and vectors
H1299 cells were plated at subconfluence in 30 mm Petri
dishes and, the day after, transfected with the expression
vectors pcDNA3, pcDNA3-p53R175H and pcDNA3-
p53R273H by using the cationic polymer Lipofectamine-
Plus method (Life Technology-Invitrogen), according to
the manufacturer’s instructions. The day after transfection
cells were treated with CPS for the indicated experiments.
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siRNA interference
U373 and SKBR3 cells were plated at semiconfluence in
35 mm dishes the day before transfection. Control pSuper
and pSuper-p53 (for p53 interference, si-p53) vectors [21]
were transfected overnight using LipofectaminePlus re-
agent (Invitrogen) and 24 h later cells were trypsinized and
replated for the indicated experiments.
Cell viability
For viability assay, subconfluent cells were plated in trip-
licate in 60 mm Petri dishes and 24 h later treated with
the indicated reagents, according to dose and time. Both
floating and adherent cells were collected and cell viability
was determined by Trypan blue exclusion by direct count-
ing with a haemocytometer. The percentage of cell death,
as blue/total cells, was assayed by scoring about 200 cells
per well in triplicate.
Chromatin-immunoprecipitation (ChIP) assay
ChIP assay was carried out essentially as previously de-
scribed [22]. Briefly, protein complexes were cross-linked
to DNA in living cells by adding formaldehyde directly to
the cell culture medium at 1 % final concentration. Chro-
matin extracts containing DNA fragments with an average
size of 500 bp were incubated overnight at 40 C with milk
shaking using polyclonal anti-p53 antibody (FL393, Santa
Cruz Biotechnology). Before use, protein G (Pierce) was
blocked with 1 μg/μL sheared herring sperm DNA and
1 μg/μL BSA for 3 h at 40 C and then incubated with chro-
matin and antibodies for 2 h at 40 C. PCR was performed
with HOT-MASTER Taq (Eppendorf) using 2 μL of immu-
niprecipitated DNA and promoter-specific primers. Immu-
noprecipitation with non-specific immunoglobulins (IgG;
Santa Cruz Biotechnology) was performed as negative con-
trols. The amount of precipitated chromatin measured in
each PCR was normalized with the amount of chromatin
present in the input of each immunoprecipitation. PCR
products were run on a 2 % agarose gel and visualized by
ethidium bromide staining using UV light.
RNA extraction and semi-quantitative reverse transcription
(RT)-PCR analysis
Cells were harvested in TRIzol Reagent (Invitrogen) and
total RNA was isolated following the manufacturer’s in-
structions. The first strand cDNA was synthesized from
2 μg of total RNA with MuLV reverse transcriptase kit (Ap-
plied Biosystems). Semi-quantitative Reverse-Transcribed
(RT)-PCR was carried out by using Hot-Master Taq
polymerase (Eppendorf ) with 2 μl cDNA reaction and
genes specific oligonucleotides under conditions of linear
amplification. PCR products were run on a 2 % agarose gel
and visualized with ethidium bromide. The housekeeping
28S gene, used as internal standard, was amplified
from the same cDNA reaction mixture. Densitometric
analysis was applied to quantify mRNA levels com-
pared to control gene expression.
Western blotting
Total cell extracts were prepared by incubation in lysis
buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 5 mM
EDTA, 150 mM KCl, 1 mM dithiothreitol, 1 % Nonidet
P-40) and a mix of protease inhibitors and resolved by
9–18 % SDS-polyacrilamide gel electrophoresis. Proteins
were transferred to a polyvinylidene difluoride membrane
(PVDF, Millipore) and membranes were blocked with 5 %
nonfat dry milk in PBS and incubated with the following
primary antibodies: monoclonal anti-poly (ADP-ribose)
polymerase (PARP, BD Pharmingen, CA, USA), monoclo-
nal anti-p53 (Ab-DO1), polyclonal anti-p53 (FL393), mono-
clonal anti-p62 (Santa Cruz Biotechnology, Dallas, TX,
USA), monoclonal anti-phospho-Histone H2AX (Ser139)
(Millipore, clone JBW301), and monoclonal anti-LC3B
(Sigma-Aldrich). Equal lane loading was monitored by
probing membranes with antibodies specific for β-actin
(Calbiochem, San Diego, CA, USA). Primary antibodies
were detected with appropriate horseradish peroxidase-
labeled secondary antibodies (Bio-Rad, Hercules, CA,
USA). Enzymatic signals were visualized using chemo-
luminescence (ECL Detection system, GE Healthcare,
Milan, Italy).
Statistical analyses
Each experiment, unless specified, was performed at least
three times. Results are expressed as values of mean ±
standard deviation (S.D.). Statistical significance was deter-
mined using Student’s t-tests for two sample comparisons
and one-way ANOVA analysis for three or more sample
comparisons.
Results
Effect of capsaicin on proliferation of cells expressing
mutant p53
We first examined the biological effect of capsaicin (CPS)
in tumor cells harbouring mutations at the hotspot codons
175 (that is, SKBR3) and 273 (that is, U373). We performed
a dose–response analysis to analyse cell viability by trypan
blue exclusion. As shown in Fig. 1a, both doses of CPS used
(100 and 200 μM) induced cell death in time-dependent
manner, although the extent of cell death was higher at
200 μM dose. Similarly, H1299 cells transfected with p53-
R175 and p53-R273 plasmids displayed increased sensitivity
to CPS, compared to H1299 cells transfected with control
vector (ctr) (Fig. 1b). Western immunoblotting revealed
PARP cleavage as soon as 16 h after treatment in both
cell lines, indicating the occurrence of apoptotic cell
death (Fig. 1c).
To determine whether the antiproliferative effect of CPS
was mediated by reactivation of mutp53, SKBR3 and
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U373 cells were transfected with control si-RNA (si-ctr)
or p53 siRNA (si-p53) expressing vectors. The p53 protein
was reduced by ≥80 % after p53 siRNA transfection
(Fig. 2a). As shown in Fig. 2b, mutp53 knockdown
strongly reduced the sensitivity to CPS-induced cell death,
whereas si-ctr cells remained highly sensitive. These re-
sults demonstrate that CPS-induced cell death in mutp53-
carrying cells was in part dependent on p53 reactivation.
CPS triggers mutant p53 protein degradation
Small-molecule compounds targeting mutp53 have been
recently used on the basis of putative conformational
changes within mutp53 proteins to restore wild-type
p53, or protein degradation through autophagy, as also
demonstrated by our studies [17, 18]. Therefore, we
investigated whether CPS could trigger mutp53 pro-
tein clearing. To this aim we evaluated the expression
of microtubule-associated protein light chain 3 (LC3)
protein that, after conversion from LC3-I to its autop-
hagosome membrane-associated lipidated form LC3-
II, is considered a cellular readout of autophagy [23].
As shown in Fig. 3a, CPS increased LC3-II protein levels
and, parallel to induction of autophagy, triggered mutp53
downregulation in both cell lines, as assessed by densito-
metric analysis (Fig. 3a, right panel). The use of chemical
inhibitor of autophagic/lysosomal degradation chloroquine
(CHQ) [23] prevented CPS-induced mutp53 degradation
(Fig. 3a and b), underlining the role of autophagy in
mutp53 degradation. In agreement, CPS induced mutp53
degradation in H1299 cells transfected with p53-R175 and
p53-R273 plasmids, along with reduction of p62 levels as
readout of autophagy induction [23] (Fig. 3b). Altogether,
these findings indicate that CPS induced mutp53 degrad-
ation through autophagy.
CPS restores wtp53 functions such as DNA binding and
transactivation of target genes
To determine whether CPS has chemical genotoxicity that
may be involved in wtp53 activation, we examined the
phosphorylation of the subtype of histone H2A, called
H2AX, in the position of Ser139 producing γH2AX, a
marker of DNA double-strand breaks [24]. Herein we
found that CPS treatment produced γH2AX expression in
both cell lines (Fig. 4a), therefore, we determined re-
activation of wtp53 functions upon CPS, by chromatin
immunoprecipitation (ChIP) assay and analysis of target
gene transcription. Binding to sequence specific DNA pro-
moters is critical for wtp53 oncosuppressor functions [25].
The results show that CPS restored p53-DNA binding ac-
tivity to the wild-type target gene promoter PUMA to the
Fig. 1 CPS induces cell death in mutp53-expressing cells in a p53-dependent manner. a U373 and SKBR3 cells were plated at subconfluence and
the day after treated with CPS (100 and 200 μM). Twenty-four hours later, the percentage of dead cells was scored by trypan blue staining. Error
bars show standard deviation. b H1299 cells were transiently transfected with pcDNA3-p53R175H (0.1 μg), pcDNA3-R273H (0.1 μg) and control
pcDNA3 vectors and the day after transfection treated with CPS (200 μM) for 24 h. Cell death measurements were assayed by Tunel assay. The results
are the mean of three independent experiments performed in triplicate ± SD. *p = 0.001. c U373 and SKBR3 cells were treated with CPS (200 μM) for
16 and 24 h. Equal amount of total cell extracts was analysed by western immunoblotting with anti-PARP antibody; the cleaved form is indicated by
the arrow. Anti-β-actin was used as protein loading control
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detriment of mutp53-activated promoter MDR1 [26]
(Fig. 4b). In agreement with the CPS-induced mutp53 au-
tophagic degradation, the use of CHQ reversed such DNA
binding. We also performed ChIP analyses using the p73
antibody because one of the mutp53 oncogenic character-
istics is to bind the family member p73 with inactivation
of p73 pro-apoptotic function [27]. Parallel to p53 results,
ChIP analyses revealed that the p73 recruitment onto
target promoters was induced after CPS treatment and
reversed by CHQ (Fig. 4b), mirroring that of reactivated
mut/wtp53. The role of autophagy in CPS-induced p53
reactivation was evaluated by measuring the transcription
of endogenous p53 target genes. The results show that the
CPS-induced wtp53 target gene Puma was efficiently
reverted by concomitant inhibition of autophagy with
chloroquine (CHQ) (Fig. 4c); in agreement, the reduction
of the mutp53 target gene MDR1 by CPS was reverted by
CHQ (Fig. 4c), in agreement with the mutant/wild-type
balance change. In addition, the specific effect of CPS in re-
activating p53 transactivation function was finally evaluated
by using the inhibitor of wtp53 transactivation function
PFT-α [19]. The results show that PFT-α indeed impaired
the increase of wtp53 target genes PUMA, Bax, and DRAM
in SKBR3 and U373 cells after CPS treatment and restored
the transcription of the mutp53 target geneMDR1 (Fig. 4c).
Altogether, these results demonstrate that CPS restores
wtp53 transcriptional activity in mutp53-carrying can-
cer cells.
CPS improves the drugs-induced tumor cell death
Finally, we evaluated the biological outcome of CPS in
combination with chemotherapeutic agents. To this aim,
SKBR3 and U373 cells were treated, respectively, with
adryamycin (ADR, 1.5 μg) and cisplatin (CDDP, 2.5 μg)
alone or in combination with CPS (100 μM) for 24 h, as
previously reported [20]. The results show that the slight
cell death effect of ADR or CDDP and CPS alone was
significantly increased when the chemotherapeutic drugs
were used in combination with CPS (Fig. 5), suggesting
that CPS-induced p53 reactivation may improve mutp53-
carrying cancer cell response to chemotherapy.
Discussion
Mutp53 proteins may drive tumor progression, metasta-
sis and resistance to therapies [4], leading to poorer
patient outcomes [28]. Therefore, reactivation of mutp53
proteins holds great promises in cancer therapy [29]. As
a proof of principle, clearing of mutp53 has been shown
to reduce tumor malignancy and to impair mutp53
gain-of-function (GOF), thus improving the apoptotic
response to drugs [30, 31]. In addition, as mutp53 pro-
teins exert a dominant negative effect on wtp53 [32],
changing the balance between folded–misfolded p53
proteins may restore wild-type over mutant p53 func-
tions, as also reported by our previous studies [17, 18,
33]. Restoration of wtp53 activity is extremely helpful for
eradicating established tumors [34–36] and does not dam-
age nontransformed cells [37]. Several small molecules
have been tested for p53 reactivation in mutp53-carrying
cells [10, 11, 38] while studies exploiting the effect of
natural compounds are limited. Here, we show that CPS,
the major constituent of peppers, induced mutp53 protein
degradation, in part through autophagy, and that such
abrogation restored wild-type p53 activities over mutant
p53 functions.
Capsaicin has been used medicinally for centuries, but
recently it has been extensively studied for its analgesic,
antioxidant, anti-inflammatory, and anti-obesity properties;
moreover, anti-cancer and pro-apoptotic effects have also
been reported [1, 13, 14, 39–42]. Recently, CPS has also
been shown to induce autophagy that eventually ends in
Fig. 2 p53 interference reduces the CPS-induced cell death in
mutp53-expressing cancer cells. a U373 and SKBR3 were transfected with
pSuper (si-ctr) or pSuper-p53 (si-p53) and 36 h after transfection equal
amount of total cell extracts was analysed by western immunoblotting
with anti-p53 antibody. Anti-β-actin was used as protein loading control.
The percentage of p53 reduction was measured by densitometry and
plotted in the right panel. b Control and interfered cells as in (a) were
treated with CPS (200 μM). Twenty-four hours later, the percentage of
dead cells was scored by trypan blue staining. Data are the mean ± S.D.
of three independent experiments performed in triplicate. *P= 0.001
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cell death [15]. In line with the biological effects of CPS,
we found that mutp53 underwent autophagy-mediated
protein degradation upon CPS treatment, as confirmed by
the use of autophagy inhibitor chloroquine that indeed
counteracted the CPS degradative effect on mutp53 restor-
ing the DNA binding and transactivation activities proper
of wtp53 protein. In response to CPS indeed, p53 transacti-
vated apoptotic genes such as Puma, Bax and DRAM to
the detriment of mutp53-activated promoter MDR1. In
addition, DRAM (damage-regulated autophagy modulator)
has been shown to induce autophagy that, in this set-
ting, may sustain mutp53 degradation, as we previously
reported [17], thus contributing to p53-dependent apop-
tosis [43]. The consequence was p53-dependent cancer
cell death in response to CPS. In addition, CPS improved
the cell death response in combination with chemothera-
peutic drug. Such effect could be exploited to reduce the
amount of chemotherapy with the aim to reduce the toxic
side effects, as we previously showed for the natural com-
pound zinc in combination with drugs [44]. Few natural
compounds have been so far found to induce mutp53
degradation [17, 18, 45, 46], and, to the best of our know-
ledge, this is the first time that CPS is shown to degrade
mutp53 protein and reactivate wtp53 in mutp53-carrying
cell lines.
Successful anticancer therapy is achieved when cancer
cells undergo apoptosis and p53 is the major player in
apoptosis induction against cancer cells [47], therefore, re-
storing wtp53 activity plays a fundamental role in antican-
cer strategies. The role of CPS in reactivating wild-type
p53 functions in mutp53-carrying cells was demonstrated
here by the use of the inhibitor of wtp53 transactivation
function, pifithrin-α (PFT-α) [19] that indeed impaired the
induction of wtp53 target genes after CPS treatment. Once
the balance between folded-misfolded p53 protein is chan-
ged to increase the wtp53 proteins, p53 can be activated.
p53 is activated in response to a variety of stress signals, in-
cluding DNA damage, hypoxia and aberrant proliferation
signals such as oncogene activation [2]. Here, CPS was
shown to induce γH2AX that in general occurs in response
to formation of double strand brakes (DSB) and is an early
sign of replication stalling [24]. In agreement, CPS has
Fig. 3 CPS induces mutp53 protein degradation. a U373 and SKBR3 cells were treated with CPS (200 μM) and chloroquine (CHQ) (25 μM) for
24 h. Protein levels were measured with western blot using antibodies to LC3-II and p53. Anti-β-actin was used as protein loading control. In the
right panel data are presented as mean ± S.D. *P = 0.001. b H1299 cells were transiently transfected with pcDNA3-p53R175H (0.1 μg), pcDNA3-R273H
(0.1 μg) and control pcDNA3 vectors and the day after transfection treated with CPS (200 μM) for 24 h. Cell death measurements were assayed by
Tunel assay. Equal amount of total cell extracts was analysed by western immunoblotting with anti-p53 and anti-p62 antibodies. Anti-β-actin was used
as protein loading control. The percentage of p53 reduction was measured by densitometry and plotted in the right panel. *P = 0.001
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Fig. 4 CPS restores wtp53 activities in mutp53-carrying cells. a U373 and SKBR3 were treated with CPS (200 μM) for 24 h. Western immunoblotting was
performed on equal amount of total cell extracts to detect phospho-Histone H2A.X (γH2AX) levels. Anti-β-actin was used as protein loading control. b
SKBR3 and U373 cells (6x106) were plated in 150 mm dish and the day after treated with CPS (200 μM) for 16 h before being assayed for
chromatin immunoprecipitation analysis (ChIP) with anti-p53 or anti-p73 antibodies. PCR analyses were performed on the immunoprecipitated DNA
samples using primers specific for wtp53 target gene promoter (Puma) or for mtp53 target promoter (MDR1). A sample representing linear amplification
of the total chromatin (Input) was included as control. Additional controls included immunoprecipitation performed with non-specific immunogloblulins
(No Ab). SKBR3 and U373 cells were plated at subconfluence in 60 mm dish and the day after treated with CPS (200 μM) for 24 h, with or
without autophagy inhibitor chloroquine (CHQ) (c) or p53 inhibitor pifithrin-α (PFT-α) (30 μM) (d). p53 target genes were detected by RT-PCR
analysis. β-actin was used as control. Gene expression was measured by densitometry, normalized to β-actin levels, ±SD (right panels) and
plotted as fold of mRNA expression over control (Mock)
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been shown to activate wtp53 that therefore contributes to
CPS-induced cell death [48, 49]. For the past several
decades, phytochemicals found in fruits, vegetables,
whole grain, spices and teas have been hot topics in
the area of chemoprevention because they exhibit a
number of inhibitory effects against cancer initiation,
promotion, progression and metastasis [50]. Moreover,
phytochemicals are readily available, inexpensive and
generally non-toxic, which gives them an advantage
with respect to pharmaceutical drugs which are indis-
criminately toxic for patient undergoing therapy and
show side-effects and drug resistance. In conclusion, we
show here for the first time that CPS is able to target
mutp53 proteins and in particular R175 mutation that
is the third most common missense p53 mutation in
human cancer and R273 that is one of the p53 muta-
tion responsible of resistance to antitumor drugs [4],
reactivating wild-type p53 oncosuppressor function.
These findings could be the used to exploit the activity
of CPS to develop novel prodrugs that could specifically
target mutp53-carrying tumors.
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